MVP方案治疗非小细胞肺癌的疗效观察

Mitomycin plus Vindesine and Cispltin in patients with Non-small cell lung cancer

摘要: 目的: 观察MVP方案治疗非小细胞肺癌(NSCLC)的治疗效果和毒性反应。方法: 45例非小细胞肺癌患者使用MVP(MMC +VDS +DDP) 方案治疗。结果: 45例患者中21例有效, 有效率为46.7 %。分析诸因素对疗效的影响发现病期早较病期晚疗效好。生活质量评估Karnofsky评分升高为68.9 %。骨髓抑制为剂量限制性毒性, 白细胞下降75.6 %无其他严重毒副反应发生。结论: MVP方案是治疗非小细胞肺癌有效且可以耐受的方案。

Abstract: Objective: Observe the therapeutic effects and toxicity reaction of MVP regimen for the treatment of non-small cell lung cancer (NSCLC). Methods: 45 cases were treated with MVP (MMC +VDS +DDP) regimen. Results: Response rates were 46.7 % (21/45). Neutropeniawas the dose-limited toxicity and was occurred in 75.6 % of cases. No other serious side reaction occurred in all patients. Conclusions: There was definitive good therapeutic effect but slight side reaction with MVP regimen in the treatment of NSCLC.